Need professional-grade analysis? Visit stockanalysis.com
$23.82M
2.37
33
N/A
Marinomed Biotech AG (MARI) trades on VI in EUR. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at EUR13.80.
Over the past year, MARI has traded between a low of EUR12.00 and a high of EUR21.00. The stock has gained 13.1% over this period. It is currently 34.3% below its 52-week high.
Marinomed Biotech AG has a market capitalization of $23.82M, with a price-to-earnings ratio of 2.37.
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company's products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; and Inhaleen for viral infection of the upper and lower respiratory tract. It also provides Solv4U which offers formulation development and biopharmaceutical testing services. It has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Side-by-side comparison against top Healthcare peers.